Introduction: This study aimed to determine the safety and efficacy of a modified technique for performing transurethral resection of the prostate (TURP) combined with percutaneous cystolithotripsy (PCCL). Methods: Clinical data from 24 patients with benign prostate hyperplasia (BPH) and aggregate stone sizes ≥3 cm were assessed retrospectively between June 2011 and January 2014. All stones fragmented via pneumatic lithotripter were removed. An 18-F Foley catheter was inserted into the Amplatz sheath, which was then removed from the bladder. The Foley catheter balloon was inflated with 15 ml of saline, and suprapubic traction was applied to prevent extravasation. Next, TURP was performed while a suprapubic Foley catheter provided continuous drainage. Results: The mean stone size was 46.25 ± 9.51 mm. The surgical duration for stone removal was 31.25 ± 8.46 min. All patients were stone-free at the first month follow-up. None of the patients experienced extravasation or urethral stricture. Conclusions: PCCL is a short-duration, minimally invasive surgery that avoids urethral stricture. In the presented technique, as the drainage catheter is fixed to the dome of bladder, it is not visualized in the surgical field and remains outside of the resection area, which facilitates prostate resection. It seems to be a safe and efficient technique.

Keywords:
Amplatz sheath, Bladder stone, Percutaneous cystolithotripsy, Transurethral prostatectomy
1.
Aron M, Agarwal MS, Goel A: Comparison of percutaneous with transurethral cystolithotripsy in patients with large prostates and large vesical calculi undergoing simultaneous transurethral prostatectomy. BJU Int 2003;91:293-295.
2.
Barnes RW, Bergman RT, Worton E: Litholapaxy vs. cystolithotomy. J Urol 1963;89:680-681.
3.
Wollin TA, Singal RK, Whelan T, Dicecco R, Razvi HA, Denstedt JD: Percutaneous suprapubic cystolithotripsy for treatment of large bladder calculi. J Endourol 1999;13:739-744.
4.
Kilciler M, Sümer F, Bedir S, Ozgök Y, Erduran D: Extracorporeal shock wave lithotripsy treatment in paraplegic patients with bladder stones. Int J Urol 2002;9:632-634.
5.
Douenias R, Rich M, Badlani G, Mazor D, Smith A: Predisposing factors in bladder calculi. Review of 100 cases. Urology 1991;37:240-243.
6.
Nseyo UO, Rivard DJ, Garlick WB, Bennett AH: Management of bladder stones: should transurethral prostatic resection be performed in combination with cystolitholapaxy? Urology 1987;29:265-267.
7.
Asci R, Aybek Z, Sarikaya S, Büyükalpelli R, Yilmaz AF: The management of vesical calculi with combined optical mechanical cystolithotripsy and transurethral prostatectomy: is it safe and effective? BJU Int 1999;84:32-36.
8.
Tugcu V, Polat H, Ozbay B, Gurbuz N, Eren GA, Tasci AI: Percutaneous versus transurethral cystolithotripsy. J Endourol 2009;23:237-241.
9.
Aron M, Goel R, Gautam G, Seth A, Gupta NP: Percutaneous versus transurethral cystolithotripsy and TURP for large prostates and large vesical calculi: refinement of technique and updated data. Int Urol Nephrol 2007;39:173-177.
10.
Zhao J, Shi L, Gao Z, Liu Q, Wang K, Zhang P: Minimally invasive surgery for patients with bulky bladder stones and large benign prostatic hyperplasia simultaneously: a novel design. Urol Int 2013;91:31-37.
11.
Sofer M, Kaver I, Greenstein A, Bar Yosef Y, Mabjeesh NJ, Chen J: Refinements in treatment of large bladder calculi: simultaneous percutaneous suprapubic and transurethral cystolithotripsy. Urology 2004;64:651-654.
12.
Kamat N: Transurethral resection of prostrate and suprapubic ballistic vesicolithotrity for benign prostatic hyperplasia with vesical calculi. J Endourol 2003;17:505-509; discussion 509.
13.
Kamat N: Comparison of percutaneous with transurethral cystolithotripsy in patients with large prostates and large vesical calculi undergoing simultaneous transurethral prostatectomy. BJU Int 2003;92:1047.
14.
Goyal NK, Goel A, Sankhwar SN: Safe percutaneous suprapubic catheterisation. Ann R Coll Surg Engl 2012;94:597-600.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.